Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

2019

55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Risk factors for heart failure in the ACE trial population
C.A.B. Scott , J.J. McMurray, L. Rydén, Y. Sun, M. Tendera, R.L. Coleman, R.R. Holman
Diabetologia 2019;62:(Supp 1):S515
[Abstract]

 

55th Annual Meeting of the European Association for the Study of Diabetes, Barcelona
Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
S. Xu, C. Scott, R.L. Coleman, J. Tuomilehto, R.R. Holman
Diabetologia 2019;62:(Supp 1):S150
[Abstract

2018

54th Annual Meeting of the European Association for the Study of Diabetes, Berlin
Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
L. Mc Morrow, F. Becker, J. Leal, A.M. Gray, R. Coleman, H.C. Gerstein, L. Rydèn, R.R. Holman
Diabetelogia 2018;61:(Suppl 1):S344
[Abstract]

2007

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
A new era in the secondary prevention of CVD in prediabetes - the Acarbose Cardiovascular Evaluation (ACE) trial
Holman RR
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S40
[Abstract]

 

2nd International Congress on Prediabetes and the Metabolic Syndrome, Barcelona
Acarbose Cardiovascular Evaluation (ACE) Trial in prediabetic subjects
Holman RR, Pan CY
Diabetes & Vascular Disease Research 2007;4:Suppl 1:S128
[Abstract]